Table 7. Univariate analyses of clinicopathologic parameters on recurrence-free and overall survival in all patients (n=1218).

		Recurrence-free survival		Overall survival
Variables	No. of patients	5-year rate (%)	P-value	5-year rate (%)	P-value
Age, years
As continuous variable	1218 (100%)		<0.001		<0.001
<30	21 (1.7%)	90	<0.001	90	<0.001
30–49	715 (58.7%)	93		96
>50	482 (39.6%)	87		90
FIGO stage
IA2	88 (7.2%)	100	<0.001	100	<0.001
IB1–IB2	1019 (83.7%)	91		93
IIA	111 (9.1%)	80		86
Histology
SCCa	996 (81.8%)	92	0.008	94	<0.001
AdCa	222 (18.2%)	86		90
Grade of differentiation a
Well	332 (27.3%)	91	0.902	93	0.967
Moderately	573 (47.0%)	91		94
Poorly	294 (24.1%)	89		92
Tumour size, cm
⩽2	571 (46.9%)	96	<0.001	97	<0.001
2–4	510 (41.9%)	88		91
4–6	114 (9.4%)	80		87
> 6	23 (1.9%)	75		77
Depth of stromal invasion
⩽1 out of 2	753 (61.8%)	94	<0.001	95	<0.001
>1 out of 2	465 (38.2%)	85		90
Parametrial involvement
No	1106 (90.8%)	92	<0.001	95	<0.001
Yes	112 (9.2%)	74		79
Resection margin
Negative	1190 (97.7%)	91	0.911	93	0.803
Positive	28 (2.2%)	89		93
LVSI
No	1048 (86.0%)	92	<0.001	94	<0.001
Yes	170 (14.0%)	85		89
Lymph node metastasis
No	1111 (85.5%)	93	<0.001	95	<0.001
Yes	188 (14.5%)	78		82
Adjuvant treatment
None	907 (74.5%)	93	<0.001	95	<0.001
Chemotherapy	86 (7.1%)	89		92
Radiation therapy	113 (9.3%)	82		85
CCRT	112 (9.2%)	80		83

Abbreviations: AdCa=adenocarcinoma; CCRT=concurrent chemoradiation therapy; FIGO=International Federation of Obstetrics and Gynecology; LVSI=lymphovascular space invasion; SCCa=squamous cell carcinoma.

^aGrade of differentiation was undetermined in 21 patients.